BD set to add HandyLab to molecular Dx offering
This article was originally published in Clinica
BD is to grow its portfolio of molecular diagnostics technology by purchasing HandyLab, a specialist in assays and automation platforms. The acquisition will follow on from an exclusive partnership between the two firms whereby BD Diagnostics aims to commercialise its molecular assays on a new platform that will integrate benchtop technology developed by Ann Arbor, Michigan-based HandyLab (www.clinica.co.uk, May 19 2009). BD said that it plans to run its GeneOhm molecular assays for methicillin-resisant Staphylococcus aureus (MRSA), Clostridium difficile and vancomycin-resistant Enterococcus (VRE) onto HandyLab’s platform and market them as the BD MAX system. Financial details of the deal, which is expected to close during the first quarter of fiscal 2010, were not disclosed.